{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:35:56Z","timestamp":1794062156146,"version":"4.8.0"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,7,15]]},"DOI":"10.2169\/internalmedicine.6353-25","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T22:07:50Z","timestamp":1766009270000},"page":"1937-1942","source":"Crossref","is-referenced-by-count":5,"title":["Characteristic Glycemic Patterns during Capivasertib Treatment Identified by Continuous Glucose Monitoring"],"prefix":"10.2169","volume":"65","author":[{"given":"Hironori","family":"Takahashi","sequence":"first","affiliation":[{"name":"Division of Diabetes and Metabolism, Sendai City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Hatayama","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Metabolism, Sendai City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Izumi","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Metabolism, Sendai City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644, 2009.","DOI":"10.1038\/nrd2926"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. He Y, Sun MM, Zhang GG, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6: 2021.","DOI":"10.1038\/s41392-021-00828-5"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Kadowaki T, Ueki K, Yamauchi T, Kubota N. SnapShot: Insulin signaling pathways. Cell 148: 624-624.e621, 2012.","DOI":"10.1016\/j.cell.2012.01.034"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 11: 873-887, 2012.","DOI":"10.1158\/1535-7163.MCT-11-0824-T"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Turner NC, Oliveira M, Howell SJ, et al.; the CAPItello-291 Study Group. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 388: 2058-2070, 2023.","DOI":"10.1056\/NEJMoa2214131"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tamura K, Hashimoto J, Tanabe Y, et al. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 77: 787-795, 2016.","DOI":"10.1007\/s00280-016-2987-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Rodriguez YE, Batra R, Patel K, Martinez S. Capivasertib-induced diabetic ketoacidosis in a patient with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative (ER+\/HER2-) metastatic breast cancer and no prior history of diabetes mellitus: a case report. Cureus 16: e63710, 2024.","DOI":"10.7759\/cureus.63710"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Chu A, Hakami-Majd N, Whall JO. Acute hyperglycemic hyperosmolar syndrome associated with capivasertib, a new, oral targeted therapy for advanced breast cancer. Am J Emerg Med 88: 273.e275-273.e277, 2025.","DOI":"10.1016\/j.ajem.2024.12.006"},{"key":"9","first-page":"e81513","volume":"17","author":"B Habeb","year":"2025","unstructured":"9. Habeb B, Valdes O, Khair S, Sidhu G, Fowler M. Capivasertib-induced diabetic ketoacidosis in a non-diabetic patient with metastatic prostate cancer with bone involvement: a case report of a rare but serious metabolic complication. Cureus 17: e81513, 2025.","journal-title":"Cureus","ISSN":"https:\/\/id.crossref.org\/issn\/2168-8184","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Andr\u00e9 F, Ciruelos E, Rubovszky G, et al.; the SOLAR-1 Study Group. Alpelisib for <i>PIK3CA<\/i>-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380: 1929-1940, 2019.","DOI":"10.1056\/NEJMoa1813904"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17: 1352-1365, 2003.","DOI":"10.1101\/gad.1089403"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lu M, Wan M, Leavens KF, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med 18: 388-395, 2012.","DOI":"10.1038\/nm.2686"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sasako T, Umehara T, Soeda K, et al. Deletion of skeletal muscle <i>Akt1\/2<\/i> causes osteosarcopenia and reduces lifespan in mice. Nat Commun 13: 5655, 2022.","DOI":"10.1038\/s41467-022-33008-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Shearin AL, Monks BR, Seale P, Birnbaum MJ. Lack of AKT in adipocytes causes severe lipodystrophy. Mol Metab 5: 472-479, 2016.","DOI":"10.1016\/j.molmet.2016.05.006"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Park J, Shin SW. Alpelisib for <i>PIK3CA<\/i>-mutated advanced breast cancer. N Engl J Med 381: 686, 2019.","DOI":"10.1056\/NEJMc1907856"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38: 1638-1642, 2015.","DOI":"10.2337\/dc15-1380"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/14\/65_6353-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:26:00Z","timestamp":1784345160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/14\/65_6353-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":16,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6353-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"6353-25"}}